5PSQ-071 Efficacy and safety evaluation of trifluridine/tiparacil for metastatic colon cancer (mcrc)

摘要

Trifluridine/tiparacile is the second oral treatment approved for patients with mCRC who have received fluoropyrimidine, oxaliplin- and irinotecan-based chemotherapy, an anti-VEGF biologic therapy and, if RAS wild-type, an anti-EGFR.